NHS Branded Medicines Tranche A - NOFE and Midlands & East and Natalizumab for London & SOFE

NHS England is procuring branded medicines under a framework agreement. Lot 1 covers Tranche A for the North of England and Midlands & East regions, with a framework period from 1 September 2026 to 31 August 2028, extendable by up to 24 months. Lot 2 covers Natalizumab for London and the South of England, with a framework period from 1 September 2026 to 31 August 2027, extendable by 12 months. The buyer is NHS England, serving the UK public health system. No specific qualifications or set-asides are mentioned, but bidders must be able to supply branded medicines and meet NHS procurement standards.